INE963

Product vision
  • Uncomplicated malaria treatment and resistance management
MoA
  • Novel and unknown
Key features
  • No cross-resistance
  • No resistant mutants identified
  • Low predicted dose, and long predicted human half-life (60 hours)
  • Fast killing in vitro and in vivo
Status
  • Phase I clinical development
Next milestone
  • Completion of first-in-human study and identification of potential combination partner
Previously
  • Discovery partnership with Novartis
  • NVP-INE963. Full reference MMV1582617
MMV Project Director
  • Dr Andrew Slade